About Organovo (NASDAQ:ONVO)
Organovo Holdings, Inc., an early commercial stage company, designs and creates functional and three-dimensional (3D) human tissues for use in medical research and therapeutic applications. The company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners. Its 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company offers two commercial products, which include ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing a suite of standardized and 3D human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology, or disease for use in drug discovery and development, and disease modeling; and 3D human tissues for clinical applications, such as therapeutic liver tissue patch. Organovo Holdings, Inc. was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Trailing P/E Ratio-3.03
Forward P/E Ratio-3.58
Sales & Book Value
Annual Sales$4.23 million
Price / Sales30.92
Price / CashN/A
Book Value$0.60 per share
Price / Book1.97
EPS (Most Recent Fiscal Year)($0.39)
Return on Equity-69.03%
Return on Assets-63.00%
Organovo (NASDAQ:ONVO) Frequently Asked Questions
What is Organovo's stock symbol?
Organovo trades on the NASDAQ under the ticker symbol "ONVO."
How were Organovo's earnings last quarter?
Organovo (NASDAQ:ONVO) issued its earnings results on Thursday, February, 8th. The medical research company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.02. The medical research company earned $1.15 million during the quarter, compared to the consensus estimate of $1.25 million. Organovo had a negative return on equity of 69.03% and a negative net margin of 881.93%. The firm's revenue was up .0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.09) EPS. View Organovo's Earnings History.
When is Organovo's next earnings date?
What price target have analysts set for ONVO?
5 analysts have issued 1 year target prices for Organovo's stock. Their forecasts range from $3.00 to $5.00. On average, they expect Organovo's share price to reach $3.9375 in the next twelve months. View Analyst Ratings for Organovo.
What are Wall Street analysts saying about Organovo stock?
Here are some recent quotes from research analysts about Organovo stock:
- 1. According to Zacks Investment Research, "Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California. " (3/9/2018)
- 2. BTIG Research analysts commented, "Reset Delays Ramp; Trimming PT From $5 to $3 We are updating our model and price target to reflect Q3 results and a slower than anticipated revenue ramp as a result of the company’s strategy focus toward fast-growing, higher margin compound screening and disease modeling. We continue to feel ONVO is a long-term investment with sizable market opportunities ($3B+) but as the technology is quite new, predicting the rate at which pharma and research partners will adopt this new technology can be tricky. As our model now incorporates more risk in the near-term given the change in strategy, our revised DCF yields a $3 PT, down from $5 previously. We maintain our Buy rating. Commentary on revenue mix is encouraging. In the call, management noted a 60%/40% split between repeat and new orders in the first half of the fiscal year, consistent with the mix seen in Fiscal 2017. Additionally, average revenue per order also continues to rise, driven by the aforementioned shift to higher value disease modeling. Finally, management also suggested the potential for a few of its clients to shift from single project to annual revenue commitment contracts over the next couple of quarters. Valuation: Our price target is $3, based on a DCF analysis that assumes a WACC of 15% and a LT growth rate of 3%. Risks follow on page 6." (11/16/2017)
Who are some of Organovo's key competitors?
Some companies that are related to Organovo include Fennec Pharmaceuticals (FENC), NanoString Technologies (NSTG), Arsanis (ASNS), ADMA Biologics (ADMA), Compugen (CGEN), Pluristem Therapeutics (PSTI), Eiger Biopharmaceuticals (EIGR), Lorus Therapeutics (APTO), Aevi Genomic Medicine (GNMX), Curis (CRIS), Applied Genetic Technologies (AGTC), Cidara Therapeutics (CDTX), aTyr Pharma (LIFE), Genocea Biosciences (GNCA), Brainstorm Cell Therapeutics (BCLI), TRACON Pharmaceuticals (TCON), CytRx (CYTR) and Vaxart (VXRT).
Who are Organovo's key executives?
Organovo's management team includes the folowing people:
- Mr. Craig Kussman MBA, Chief Financial Officer (Age 59)
- Dr. Sharon Collins Presnell Ph.D., Chief Scientific Officer (Age 49)
- Ms. Jennifer Kinsbruner Bush J.D., Sr. VP, Gen. Counsel, Corp. Sec. & Compliance Officer (Age 43)
- Mr. Taylor J. Crouch, CEO, Pres & Director (Age 58)
- Steve E. Kunszabo, VP of Investor Relations & Corp. Communications
Has Organovo been receiving favorable news coverage?
Media stories about ONVO stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Organovo earned a news impact score of 0.15 on Accern's scale. They also assigned news headlines about the medical research company an impact score of 46.40 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Organovo?
Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Organovo's stock price today?
One share of ONVO stock can currently be purchased for approximately $1.18.
How big of a company is Organovo?
Organovo has a market capitalization of $130.79 million and generates $4.23 million in revenue each year. The medical research company earns $-38,440,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Organovo employs 113 workers across the globe.
How can I contact Organovo?
Organovo's mailing address is 6275 NANCY RIDGE DRIVE SUITE 110, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]
MarketBeat Community Rating for Organovo (ONVO)MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote "Outperform" if you believe ONVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Organovo (NASDAQ:ONVO) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Organovo (NASDAQ ONVO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.20%
Institutional Ownership Percentage: 24.85%
Organovo (NASDAQ ONVO) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/9/2017||Keith Murphy||CEO||Sell||25,000||$3.68||$92,000.00|| |
|1/24/2017||Keith Murphy||CEO||Sell||25,000||$3.51||$87,750.00||6,059,015|| |
|12/14/2016||Keith Murphy||CEO||Sell||50,000||$3.72||$186,000.00|| |
|8/5/2016||Eric David||EVP||Sell||20,000||$4.55||$91,000.00|| |
Organovo (NASDAQ ONVO) News Headlines
|Can The Uptrend Continue for Organovo Holdings (ONVO)?|
finance.yahoo.com - April 18 at 5:47 PM
|Organovo Holdings Inc (ONVO) Expected to Post Quarterly Sales of $1.33 Million|
www.americanbankingnews.com - April 18 at 3:04 AM
|BidaskClub Lowers Organovo (ONVO) to Strong Sell|
www.americanbankingnews.com - April 16 at 1:54 PM
|Organovo Holdings Inc (ONVO) Expected to Post Earnings of -$0.07 Per Share|
www.americanbankingnews.com - April 16 at 1:12 PM
|Organovo (ONVO) Reports Key Development Milestones for Its Liver Disease and Intestinal Tissue Models|
www.streetinsider.com - April 16 at 8:13 AM
|Organovo (ONVO) 3D Bioprinting Capabilities Highlighted in Cirius Therapeutics' Preclinical Data Demonstration for ...|
www.streetinsider.com - April 12 at 5:41 PM
|Organovo Presents Data on Modeling Liver Disease Using 3D Bioprinted Human Liver Tissue at The International ...|
www.globenewswire.com - April 12 at 8:32 AM
|Cirius Therapeutics' Preclinical Data Demonstrates Potential for Lead Drug Candidate MSDC-0602K in NASH|
finance.yahoo.com - April 12 at 8:32 AM
|Organovo Presents Data on Modeling Liver Disease Using 3D Bioprinted Human Liver Tissue at The International Liver Congress™|
finance.yahoo.com - April 12 at 8:32 AM
|Edited Transcript of ONVO earnings conference call or presentation 8-Feb-18 10:00pm GMT|
finance.yahoo.com - April 1 at 8:16 AM
|$1.33 Million in Sales Expected for Organovo Holdings Inc (ONVO) This Quarter|
www.americanbankingnews.com - April 1 at 3:42 AM
|Organovo Holdings Inc (ONVO) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - April 1 at 1:54 AM
|-$0.07 EPS Expected for Organovo Holdings Inc (ONVO) This Quarter|
www.americanbankingnews.com - March 30 at 3:10 PM
|Organovo Division Samsara Sciences Announces Multi-Year Supply Agreement With Lonza Bioscience Solutions|
finance.yahoo.com - March 26 at 8:19 AM
|Organovo to Present at HC Wainwright Nash Investor Conference - GlobeNewswire (press release)|
globenewswire.com - March 16 at 8:15 AM
|Organovo to Present at H.C. Wainwright Nash Investor Conference|
finance.yahoo.com - March 15 at 8:13 AM
|Zacks: Analysts Anticipate Organovo Holdings Inc (ONVO) to Announce -$0.07 Earnings Per Share|
www.americanbankingnews.com - March 13 at 11:49 AM
|Organovo (ONVO) Downgraded to Hold at Zacks Investment Research|
www.americanbankingnews.com - March 10 at 4:20 PM
|Organovo to Present at 30th Annual ROTH Conference - GlobeNewswire (press release)|
globenewswire.com - March 9 at 8:16 AM
|Zacks Investment Research Upgrades Organovo (ONVO) to Buy|
www.americanbankingnews.com - March 8 at 10:42 AM
|Organovo to Present at 30th Annual ROTH Conference - Nasdaq|
www.nasdaq.com - March 8 at 8:20 AM
|Organovo Holdings Inc (ONVO) Receives Average Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - March 7 at 1:52 AM
|This Morning's Technical Outlook on Medical Research Stocks -- Laboratory Corp. of America, Organovo, PerkinElmer ... - PR Newswire (press release)|
www.prnewswire.com - February 27 at 8:15 AM
|ARK Investment Management LLC Boosts Stake in Organovo Holdings Inc (ONVO)|
www.americanbankingnews.com - February 27 at 4:24 AM
|Zacks: Brokerages Expect Organovo Holdings Inc (ONVO) Will Post Quarterly Sales of $1.33 Million|
www.americanbankingnews.com - February 26 at 9:06 AM
|Organovo (ONVO) Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - February 17 at 6:24 AM
|Organovo (ONVO) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - February 16 at 6:46 AM
|Jefferies Group Weighs in on Organovo Holdings Inc's FY2018 Earnings (ONVO)|
www.americanbankingnews.com - February 15 at 11:20 AM
|Early Breakthroughs Indicate 2018 Will be a Strong Year for 3D Tech|
www.prnewswire.com - February 14 at 9:34 AM
|Organovo Holdings Inc (ONVO) Given Average Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - February 10 at 1:48 AM
|Organovo (ONVO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS|
www.americanbankingnews.com - February 9 at 12:23 PM
|Organovo Announces Fiscal Third-Quarter 2018 Results; Company Updates Full-Year Fiscal 2018 Outlook|
finance.yahoo.com - February 9 at 9:33 AM
|Organovo Holdings Inc (ONVO) Expected to Post Quarterly Sales of $1.23 Million|
www.americanbankingnews.com - February 9 at 2:50 AM
|A Preview Of Organovo's Q3 Earnings|
finance.yahoo.com - February 8 at 3:40 PM
|Organovo Holdings, Inc. to Host Earnings Call|
finance.yahoo.com - February 8 at 3:40 PM
| Analysts Anticipate Organovo Holdings Inc (ONVO) to Announce -$0.10 EPS|
www.americanbankingnews.com - February 7 at 1:35 PM
|Organovo (ONVO) Set to Announce Earnings on Wednesday|
www.americanbankingnews.com - January 31 at 2:48 AM
|Organovo Announces Release Date for Fiscal Third-Quarter 2018 Financial Results|
finance.yahoo.com - January 26 at 8:59 AM
|Zacks: Brokerages Anticipate Organovo Holdings Inc (ONVO) Will Announce Quarterly Sales of $1.23 Million|
www.americanbankingnews.com - January 23 at 6:26 AM
|Organovo (ONVO) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - December 28 at 11:42 PM
|ETFs with exposure to Organovo Holdings, Inc. : December 28, 2017|
finance.yahoo.com - December 28 at 12:54 PM
|Organovo Holdings, Inc. :ONVO-US: Earnings Analysis: Q2, 2018 By the Numbers : December 27, 2017|
finance.yahoo.com - December 27 at 1:06 PM
|Organovo (ONVO) Granted Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency|
www.streetinsider.com - December 26 at 10:11 AM
|32 Stocks Moving In Tuesday's Pre-Market Session|
feeds.benzinga.com - December 26 at 9:30 AM
|Organovo Holdings Inc (ONVO) Receives Consensus Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - December 22 at 2:06 AM
|$1.23 Million in Sales Expected for Organovo Holdings Inc (ONVO) This Quarter|
www.americanbankingnews.com - December 21 at 10:54 AM
|Zacks: Brokerages Expect Organovo Holdings Inc (ONVO) Will Announce Earnings of -$0.10 Per Share|
www.americanbankingnews.com - December 19 at 5:20 AM
|ETFs with exposure to Organovo Holdings, Inc. : December 15, 2017|
finance.yahoo.com - December 15 at 4:47 PM
|Where Will Organovo Holdings, Inc. Be in 5 Years?|
www.fool.com - December 3 at 3:03 PM
|Organovo Holdings, Inc. (ONVO) Given Average Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - November 27 at 2:06 AM
Organovo (NASDAQ:ONVO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Organovo (NASDAQ ONVO) Stock Chart for Sunday, April, 22, 2018